Page last updated: 2024-12-08

fengycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fengycin: lipopeptide from Bacillus subtilis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID443591
CHEBI ID29583
MeSH IDM0142950

Synonyms (6)

Synonym
102577-03-7
fengycin
fengymycin
fengycin c
CHEBI:29583
Q27110158

Research Excerpts

Overview

Fengycins are a class of antifungal lipopeptides synthesized by the bacteria Bacillus subtilis. Fengycin is commercially available as the primary component of the agricultural fungicide Serenade.

ExcerptReferenceRelevance
"Fengycins are a class of antifungal lipopeptides synthesized by the bacteria Bacillus subtilis, commercially available as the primary component of the agricultural fungicide Serenade. "( Effects of cholesterol on the mechanism of fengycin, a biofungicide.
Grossfield, A; Sur, S, 2022
)
2.43
"Fengycin is a lipopeptide produced by "( Transcriptome Analysis of
Bilal, M; Geng, C; Gu, C; Liu, S; Lu, H; Xu, H; Yang, P; Zhao, L; Zhao, Y; Zhong, M; Zhu, S, 2022
)
2.16
"Fengycin is a cyclic lipopeptide used as an agricultural fungicide. "( Selectivity and Mechanism of Fengycin, an Antimicrobial Lipopeptide, from Molecular Dynamics.
Grossfield, A; Romo, TD; Sur, S, 2018
)
2.21
"Fengycin is an antimicrobial cyclic lipopeptide known to interact with microbial cell membranes. "( Supported lipid bilayers using extracted microbial lipids: domain redistribution in the presence of fengycin.
Avis, TJ; Crippin, T; Mantil, E, 2019
)
2.17
"Fengycin is a natural lipopeptide with antifungal and eliciting properties and able to inhibit the activity of phospholipase A2. "( Analysis of calcium-induced effects on the conformation of fengycin.
Deleu, M; Flore, C; Laurent, P; Lins, L; Nasir, MN; Ongena, M, 2013
)
2.08
"Fengycin is an antimicrobial cyclic lipopeptide produced by various Bacillus subtilis strains, including strain CU12. "( Cellular Lipid Composition Affects Sensitivity of Plant Pathogens to Fengycin, an Antifungal Compound Produced by Bacillus subtilis Strain CU12.
Avis, TJ; Falardeau, J; Hagberg, I; Wise, C, 2014
)
2.08
"Fengycin is a lipopeptide antibiotic synthesized nonribosomally by five fengycin synthetases. "( Regions involved in fengycin synthetases enzyme complex formation.
Cheng, YC; Ke, WJ; Liu, ST, 2017
)
2.22
"Fengycin is a promising antifungal lipopeptide from Bacillus spp. "( Influence of promoters on the production of fengycin in Bacillus spp.
Béchet, M; Drider, D; Gancel, F; Jacques, P; Yaseen, Y, 2016
)
2.14
"Fengycin is a cyclic lipopeptidic antibiotic produced nonribosomally by Bacillus subtilis. "( Functional analysis of fengycin synthetase FenD.
Chang, LK; Chen, CL; Fu, HC; Huang, SH; Lin, GH; Lin, TP; Liu, ST; Wu, CY, 2005
)
2.08
"Fengycin is a biologically active lipopeptide produced by several Bacillus subtilis strains. "( Effect of fengycin, a lipopeptide produced by Bacillus subtilis, on model biomembranes.
Deleu, M; Nylander, T; Paquot, M, 2008
)
2.19
"Fengycin is an antifungal lipopeptide complex produced by Bacillus subtilis strain F-29-3. "( Fengycin--a novel antifungal lipopeptide antibiotic produced by Bacillus subtilis F-29-3.
Jung, G; Koch, U; Loeffler, W; Vanittanakom, N, 1986
)
3.16

Actions

Fengycin can inhibit the growth of the cancer cell line 95D by regulating the cell cycle and promoting apoptosis. Fengycin may have potential as an anticancer treatment.

ExcerptReferenceRelevance
"Fengycin antibiotic displays a strong antifungal activity and inhibits the growth of a wide range of plant pathogens especially filamentous fungi. "( Characterization of New Fengycin Cyclic Lipopeptide Variants Produced by Bacillus amyloliquefaciens (ET) Originating from a Salt Lake of Eastern Algeria.
Ait Kaki, A; De Pauw, E; Kacem Chaouche, N; Kara Ali, M; Moula, N; Ongena, M; Smargiasso, N, 2020
)
2.31
"Fengycin can inhibit the growth of the cancer cell line 95D by regulating the cell cycle and promoting apoptosis, suggesting that it may have potential as an anticancer treatment."( Fengycin inhibits the growth of the human lung cancer cell line 95D through reactive oxygen species production and mitochondria-dependent apoptosis.
Guo, C; Liu, D; Lu, Z; Lv, F; Lv, Y; Wang, Y; Yin, H, 2013
)
2.55

Treatment

ExcerptReferenceRelevance
"Treatment with fengycin not only significantly decreased cell proliferation in various cancer cell lines including 95D but inhibited the growth of xenografted 95D cells in nude mice."( Fengycin inhibits the growth of the human lung cancer cell line 95D through reactive oxygen species production and mitochondria-dependent apoptosis.
Guo, C; Liu, D; Lu, Z; Lv, F; Lv, Y; Wang, Y; Yin, H, 2013
)
2.17

Bioavailability

ExcerptReferenceRelevance
") Second, a cosurfactant may enhance the bioavailability of a poorly soluble peptide."( Additive and synergistic membrane permeabilization by antimicrobial (lipo)peptides and detergents.
Bärlehner, D; Heerklotz, H; Huynh, Q; Patel, H, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
cyclodepsipeptideA depsipeptide in which the amino and hydroxy carboxylic acid residues are connected in a ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (166)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.60)18.7374
1990's5 (3.01)18.2507
2000's30 (18.07)29.6817
2010's105 (63.25)24.3611
2020's25 (15.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.82 (24.57)
Research Supply Index5.14 (2.92)
Research Growth Index5.71 (4.65)
Search Engine Demand Index50.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (1.78%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other166 (98.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]